Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > generic: None

& fda max

: 10 mg/d

or 400 mg/d (pediatric); 600 mg/d (adult)

Use the filters below to narrow your results.

Dayvigo (1) · Qelbree (1)

Dual orexin receptor antagonist (DORA) (1) · non-stimulant ADHD agent (1) · Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism (1)

Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. (1)

ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1)

5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1)

100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food) (1) · 5 mg, 10 mg tablets (1)

Oral (2)

ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks) (1) · ~30 min (1)

Daily dosing (1) · ~7-8 hours (1)

~17-19 hours (longer than daridorexant) (1) · ~7 hours (1)

Adequate oral bioavailability with extended-release formulation (1) · ~44% (1)

Limited data (1) · Limited data; avoid (1)

Rx, '''not a controlled substance''' (no DEA scheduling) (1) · Rx, Schedule IV (US) (1)

Showing below up to 2 results in range #1 to #2.

L

Lemborexant

V

Viloxazine

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"